MM-111
- Generic Name
- MM-111
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1361108-53-3
- Unique Ingredient Identifier
- 6IJ4CQY76O
- Background
MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 84
- Registration Number
- NCT01774851
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00911898
- Locations
- 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Indiana University (IUPUI), Indianapolis, Indiana, United States
🇺🇸Fox Chase Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath